Patricia Van Arnum

Fine-chemical manufacturers producers and contract manufacturers roll out manufacturing and service expansions at CPhI in Madrid.

Recent research on elucidating the structure and sequence of proteins involves examining the effect of microgravity on protein crystallization and a computational model for protein elucidation.

Particle-engineering technologies, such as crystal design for crystallization and producting cocrystals, particle-size reduction, and amorphous solid dispersions, help to optimize delivery of a drug.

Fixed-dose combination drug therapies give rise to innovation in solid-dosage formulations and manufacturing.

The physical form of an API is an important consideration in formulation development. Particle-engineering technologies, such as crystal design for controlling crystallisation and producing cocrystals, particle-size reduction and amorphous solid dispersions, help to optimise delivery of a drug.

Watson Laboratories has recalled two lots of hydrocodone bitartrate and acetaminophen tablets.

Innovation is the cornerstone of the pharmaceutical industry.

A look at PharmaCheck, a field-based tool in development that uses microfluidic chip technology for assessing the quality of medicine in the developing world.

Although serving niche areas, orphan drugs offer good market opportunities for pharmaceutical companies and their suppliers.

The Generic Drug User Fee Act seeks to improve and enhance regulatory activities, including achieving parity of inspections between foreign and domestic drug-manufacturing sites for both finished dosage forms and APIs of generic drugs.

A roundup of the latest developments for drug delivery of parenteral drugs.

Bristol-Myers Squibb has initiated a voluntary recall of 10 lots of BiCNU (carmustine for injection) previously manufactured by Ben Venue Laboratories, a former, third-party contract manufacturer for the company, to the user level.

Researchers have developed injectable, reformable, and spreadable hydrogels capable of delivering sustained release of the proteins they contain for up to six months.

Advances in targeted drug delivery and customized release profiles are key industry goals.

Industry experts share perspectives on analytical instrumentation, methods, and data analysis.

Industry and academia advance novel approaches for achieving enanioselectivity.

Pfizer has two manufacturing facilities in Germany for high-potency manufacturing, respectively in Freiburg and Illertissen. Pharmaceutical Technology's Executive Editor Patricia Van Arnum visited the facilities and spoke to the company about the design and operation of these facilities.

Experts share insight on facility design and operations for high-potency manufacturing.

A Q&A with BASF moderated by Patricia Van Arnum.

An industry roundtable representing Metrics, Cambrex, Carbogen Amcis, Euticals, Ferro Pfanstiehl, and SAFC.

The author discusses the key provisions of GDUFA as they relate to the pharmaceutical supply chain, including parity of inspections between domestic and foreign sites for both finished dosage forms and APIs of generic drugs.

Eli Lilly has received $1.3 billion for payment of financial obligations from Amylin Pharmaceuticals following Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals earlier this month.

Myriad Genetics reported that a US federal appeals court has ruled that the company's composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under federal patent law. The court, however, denied the company's effort to patent methods of "comparing" or "analyzing" DNA sequences.

An internal investigation and voluntary disclosure by Pfizer led to a settlement with the US Department of Justice and Securities and Exchange Commission.

Approaches to scaling up API syntheses center on ways to optimize process conditions and operability.

Pharmaceutical Technology's annual manufacturing investment update shows slight gains in biopharmaceutical manufacturing and emerging markets and continued restructuring of supply networks.

Enhancing bioavailability can be achieved through hot-melt extrusion or spray drying. Patricia Van Arnum interviews Bend Research to find out more about when to use each technique.

The manufacturing capacity-sharing model in biologics and Merck & Co. and MedImmune ushers in a new paradigm of "co-opetition".

An examination of the current and projected market for biosimilars, development costs for biosimilars compared with small-molecule generic drug, and partnerships in biosimilars.

AMRI, a contract research and manufacturing organization, discusses its adaption of an insourcing model with Eli Lilly.